Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium.
Babic A, Cramer DW, Kelemen LE, Köbel M, Steed H, Webb PM, Johnatty SE, deFazio A, Lambrechts D, Goodman MT, Heitz F, Matsuo K, Hosono S, Karlan BY, Jensen A, Kjær SK, Goode EL, Pejovic T, Moffitt M, Høgdall E, Høgdall C, McNeish I, Terry KL. Babic A, et al. Among authors: defazio a. Cancer Causes Control. 2017 May;28(5):459-468. doi: 10.1007/s10552-016-0841-3. Epub 2017 Jan 3. Cancer Causes Control. 2017. PMID: 28050675 Free PMC article.
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I; Australian Ovarian Cancer Study Group; Gertig D, DeFazio A, Bowtell DD. Tothill RW, et al. Among authors: defazio a. Clin Cancer Res. 2008 Aug 15;14(16):5198-208. doi: 10.1158/1078-0432.CCR-08-0196. Clin Cancer Res. 2008. PMID: 18698038
ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.
Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, Byth K, Marsh S, McLeod H; AOCS Study Group; Harnett PR, Brown R, DeFazio A, Chenevix-Trench G. Johnatty SE, et al. Among authors: defazio a. Clin Cancer Res. 2008 Sep 1;14(17):5594-601. doi: 10.1158/1078-0432.CCR-08-0606. Clin Cancer Res. 2008. PMID: 18765553 Free article.
Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.
Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, Lade S, Akslen LA, Tinker AV, Locandro B, Alsop K, Chiew YE, Traficante N, Fereday S, Johnson D, Fox S, Sellers W, Urashima M, Salvesen HB, Meyerson M, Bowtell D; AOCS Study Group. Etemadmoghadam D, et al. Among authors: defazio a. Clin Cancer Res. 2009 Feb 15;15(4):1417-27. doi: 10.1158/1078-0432.CCR-08-1564. Epub 2009 Feb 3. Clin Cancer Res. 2009. PMID: 19193619 Free PMC article.
Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium.
Johnatty SE, Beesley J, Chen X, Spurdle AB, Defazio A, Webb PM; Australian Ovarian Cancer Study Group; Australian Cancer Study (Ovarian Cancer); Goode EL, Rider DN, Vierkant RA, Anderson S, Wu AH, Pike M, Van Den Berg D, Moysich K, Ness R, Doherty J, Rossing MA, Pearce CL, Chenevix-Trench G. Johnatty SE, et al. Among authors: defazio a. Twin Res Hum Genet. 2009 Jun;12(3):269-75. doi: 10.1375/twin.12.3.269. Twin Res Hum Genet. 2009. PMID: 19456219 Free PMC article.
Prevalence and predictors of insomnia in women with invasive ovarian cancer: anxiety a major factor.
Price MA, Zachariae R, Butow PN, deFazio A, Chauhan D, Espie CA, Friedlander M, Webb PM; Australian Ovarian Cancer Study Group; Australian Ovarian Cancer Study - Quality of Life Study Investigators. Price MA, et al. Among authors: defazio a. Eur J Cancer. 2009 Dec;45(18):3262-70. doi: 10.1016/j.ejca.2009.05.030. Epub 2009 Jun 18. Eur J Cancer. 2009. PMID: 19540748
Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot".
Johnatty SE, Beesley J, Chen X, Macgregor S, Duffy DL, Spurdle AB, deFazio A, Gava N, Webb PM, Rossing MA, Doherty JA, Goodman MT, Lurie G, Thompson PJ, Wilkens LR, Ness RB, Moysich KB, Chang-Claude J, Wang-Gohrke S, Cramer DW, Terry KL, Hankinson SE, Tworoger SS, Garcia-Closas M, Yang H, Lissowska J, Chanock SJ, Pharoah PD, Song H, Whitemore AS, Pearce CL, Stram DO, Wu AH, Pike MC, Gayther SA, Ramus SJ, Menon U, Gentry-Maharaj A, Anton-Culver H, Ziogas A, Hogdall E, Kjaer SK, Hogdall C, Berchuck A, Schildkraut JM, Iversen ES, Moorman PG, Phelan CM, Sellers TA, Cunningham JM, Vierkant RA, Rider DN, Goode EL, Haviv I, Chenevix-Trench G; Ovarian Cancer Association Consortium; Australian Ovarian Cancer Study Group; Australian Cancer Study (Ovarian Cancer). Johnatty SE, et al. Among authors: defazio a. PLoS Genet. 2010 Jul 8;6(7):e1001016. doi: 10.1371/journal.pgen.1001016. PLoS Genet. 2010. PMID: 20628624 Free PMC article.
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.
Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG; Australian Ovarian Cancer Study Group; Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD. Anglesio MS, et al. Clin Cancer Res. 2011 Apr 15;17(8):2538-48. doi: 10.1158/1078-0432.CCR-10-3314. Epub 2011 Feb 22. Clin Cancer Res. 2011. PMID: 21343371 Clinical Trial.
295 results